# A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis

> **NCT02087059** · PHASE3 · COMPLETED · sponsor: **Novartis Pharmaceuticals** · enrollment: 51 (actual)

## Conditions studied

- Primary Myelofibrosis (MF)

## Interventions

- **DRUG:** Ruxolitinib

## Key facts

- **NCT ID:** NCT02087059
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-04
- **Primary completion:** 2015-03
- **Final completion:** 2015-04
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2016-07-11


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02087059

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02087059, "A Clinical Study of Ruxolitinib in Patients With Primary Myelofibrosis (PM), Post-polycythemia Vera (PV) Myelofibrosis, or Post-essential Thrombocythemia (ET) Myelofibrosis". Retrieved via AI Analytics 2026-07-05 from https://api.ai-analytics.org/clinical/NCT02087059. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*